Traws Pharma Future Growth

Future criteria checks 0/6

Traws Pharma is forecast to grow revenue at 1% per annum. EPS is expected to grow by 87.5% per annum.

Key information

n/a

Earnings growth rate

87.5%

EPS growth rate

Pharmaceuticals earnings growth	23.7%
Revenue growth rate	1.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	09 Oct 2024

Recent future growth updates

Recent updates

We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Mar 09

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

Apr 22

Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans

Jul 27

Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?

Mar 21

Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth

Dec 06

Earnings and Revenue Growth Forecasts

NasdaqCM:TRAW - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	0	N/A	N/A	N/A	1
12/31/2024	0	N/A	N/A	N/A	1
9/30/2024	0	-141	N/A	N/A	N/A
6/30/2024	0	-137	-23	-23	N/A
3/31/2024	0	-18	-18	-18	N/A
12/31/2023	0	-19	-18	-18	N/A
9/30/2023	0	-20	-17	-17	N/A
6/30/2023	0	-21	-17	-17	N/A
3/31/2023	0	-21	-17	-17	N/A
12/31/2022	0	-19	-16	-16	N/A
9/30/2022	0	-17	-17	-17	N/A
6/30/2022	0	-15	-17	-17	N/A
3/31/2022	0	-16	-17	-17	N/A
12/31/2021	0	-16	-19	-19	N/A
9/30/2021	0	-19	-21	-21	N/A
6/30/2021	0	-22	-22	-22	N/A
3/31/2021	0	-25	-23	-23	N/A
12/31/2020	0	-25	-23	-23	N/A
9/30/2020	0	-24	-23	-23	N/A
6/30/2020	0	-23	-21	-21	N/A
3/31/2020	2	-19	-21	-21	N/A
12/31/2019	2	-22	-21	-21	N/A
9/30/2019	2	-21	-21	-21	N/A
6/30/2019	2	-22	-24	-24	N/A
3/31/2019	1	-23	-24	-24	N/A
12/31/2018	1	-21	-23	-23	N/A
9/30/2018	1	-21	-22	-22	N/A
6/30/2018	1	-23	N/A	-22	N/A
3/31/2018	1	-21	N/A	-23	N/A
12/31/2017	1	-24	N/A	-24	N/A
9/30/2017	1	-23	N/A	-24	N/A
6/30/2017	2	-18	N/A	-19	N/A
3/31/2017	4	-21	N/A	-17	N/A
12/31/2016	6	-20	N/A	-16	N/A
9/30/2016	15	-11	N/A	-16	N/A
6/30/2016	15	-15	N/A	-22	N/A
3/31/2016	13	-19	N/A	-26	N/A
12/31/2015	11	-24	N/A	-31	N/A
9/30/2015	2	-41	N/A	-40	N/A
6/30/2015	0	-50	N/A	-46	N/A
3/31/2015	0	-57	N/A	-51	N/A
12/31/2014	1	-64	N/A	-58	N/A
9/30/2014	3	-65	N/A	-61	N/A
6/30/2014	4	-71	N/A	-62	N/A
3/31/2014	4	-68	N/A	-64	N/A
12/31/2013	5	-65	N/A	-61	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if TRAW's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if TRAW's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if TRAW's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TRAW's revenue (1% per year) is forecast to grow slower than the US market (9% per year).

High Growth Revenue: TRAW's revenue (1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TRAW's Return on Equity is forecast to be high in 3 years time

Traws Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 22% to US$6.50

Consensus revenue estimates decrease by 19%, EPS upgraded

Consensus EPS estimates upgraded to US$0.97 loss

Consensus revenue estimates fall by 13%

Consensus forecasts updated

Price target decreased to US$8.67

Recent updates

Traws Pharma Receives Non-Compliance Letter from Nasdaq Regarding Non-Compliance with the Minimum $2.5 Million Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Traws Pharma, Inc., Annual General Meeting, Oct 31, 2024

Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma, Inc. Announces Positive Topline Phase 1 Results for Covid Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Nasdaq Determines to Delist Traws Pharma's Securities

Traws Pharma, Inc. Announces Board Changes

Traws Pharma Receives Letter from The Nasdaq Capital Market Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Traws Pharma, Inc. announced delayed 10-Q filing

Traws Pharma, Inc. to Report Q2, 2024 Results on Aug 15, 2024

Price target decreased by 22% to US$6.50

New minor risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy

High number of new directors

Consensus revenue estimates decrease by 19%, EPS upgraded

Traws Pharma, Inc. Announces Chief Executive Office Changes

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Onconova Therapeutics, Inc and Trawsfynydd Therapeutics, Inc. Announce Management Appointments for the Combined Company Traws Pharma, Inc

We're Keeping An Eye On Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Rate

Onconova TherapeuticsNarazaciclib Ash Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

Consensus EPS estimates upgraded to US$0.97 loss

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Onconova Therapeutics, Inc. Appoints Victor Moyo as Chief Medical Officer

Onconova Therapeutics Receives A Letter from the Nasdaq Capital Market Regarding Minimum Bid Price Requirement

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Onconova Therapeutics, Inc. Presents Preclinical Data on Narazaciclib at the 17Th International Conference on Malignant Lymphoma

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2023

Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Here's Why We're Watching Onconova Therapeutics' (NASDAQ:ONTX) Cash Burn Situation

Consensus revenue estimates fall by 13%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Onconova Therapeutics, Inc. Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma

Insufficient new directors

Onconova Therapeutics, Inc. Announces Board Appointments

Consensus forecasts updated

Price target decreased to US$8.67

Onconova Therapeutics, Inc. Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Onconova Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Onconova Therapeutics, Inc. Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

Onconova Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Onconova Therapeutics (NASDAQ:ONTX) Is In A Good Position To Deliver On Growth Plans

Onconova Therapeutics, Inc., Annual General Meeting, Aug 18, 2022

Onconova Therapeutics, Inc. Announces Executive Changes

Onconova Therapeutics, Inc., Annual General Meeting, Jul 21, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Onconova Therapeutics, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$10.00

Will Onconova Therapeutics (NASDAQ:ONTX) Spend Its Cash Wisely?

Companies Like Onconova Therapeutics (NASDAQ:ONTX) Are In A Position To Invest In Growth

Price target decreased to US$11.50

Onconova Therapeutics Announces the Presentation of Preliminary Clinical Data Providing Evidence of Rigosertib’s Activity in RDEB-associated Squamous Cell Carcinoma

Onconova Therapeutics, Inc. Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Onconova Therapeutics, Inc. Announces the Publication of a Preclinical Study in the Journal Molecular Cancer

Onconova Therapeutics names Mark Gelder as chief medical officer

Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300

Onconova Therapeutics, Inc. to Report Fiscal Year 2020 Results on Mar 11, 2021

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

Onconova Therapeutics, Inc. Announces Resignation of Richard C. Woodman, MD, Senior Vice President Chief Medical Officer

Onconova Therapeutics announces $8.7M registered direct offering

Onconova cleared to start Phase 1 trial for cancer therapy

Onconova Therapeutics, Inc. Announces FDA Permission for Study to Proceed Under its Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300